04:11 AM EST, 11/05/2025 (MT Newswires) -- Novo Nordisk ( NVO ) reported Q3 earnings Wednesday of 4.50 Danish kroner ($0.69) per diluted share, down from 6.12 kroner a year earlier.

Analysts polled by FactSet expected 4.90 kroner.

Revenue for the quarter ended Sept. 30 was 74.98 billion kroner, compared with 71.31 billion kroner a year earlier.

Analysts surveyed by FactSet expected 76.49 billion kroner.

The company said it expects 2025 sales growth guidance of 8% to 11% at constant exchange rates compared with a previous range of 8% to 14% driven by lower growth expectations for its GLP-1 treatments within diabetes and obesity.

Analysts surveyed by FactSet expected 312.92 billion kroner.

Shares were 2% higher in premarket activity Wednesday.